2 results
Approved WMOCompleted
Primary Objective To determine whether the combination of Onartuzumab + * erlotinib is superior (in terms of OS) to placebo * erlotinib after standard platinum-based chemotherapy in patients with Met diagnostic*positive non*small cell lung cancer (…
Approved WMOPending
Main objective: To determine the efficacy of pemigatinib in participants with recurrent GBM with an activating FGFR1-3 mutation or fusion/rearrangement. Secondary objectives: 1. To determine the efficacy of pemigatinib in participants with recurrent…